16414-04-3

Upstream product

• 849585-22-4 LACTIC ACID 
• 39145-59-0 o-phenylenediamine hydrochloride 
• 95-54-5 1,2-diamino-benzene 
• 97-64-3 ethyl 2-hydroxypropionate 
• 300-85-6 3-Hydroxybutyric acid 
• 88-74-4 2-nitro-aniline 

Downstream Products

• 2849-93-6 2-benzimidazolecarboxylic acid 
• 19275-82-2 2-(1-chloroethyl)-1H-benzo[d]imidazole 
• 128452-54-0 6,13-dimethyl-5H,12H-pyrazino<1,2-a:4,5-a'>bis-benzimidazole 
• 14984-26-0 2-ethenyl-1H-1,3-benzodiazole 
• 56653-47-5 N-benzyl-2-(α-hydroxyethyl)benzimidazole 
• 3319-28-6 N-methyl-2-(α-hydroxyethyl)benzimidazole 
• 341495-51-0 1-(1H-benzoimidazol-2-yl)-2,3-dibromo-3-phenyl-propan-1-one 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of aromatic amide-substituted benzimidazole-derived chalcones. The effect of upregulating TP53 protein expression

A series of benzimidazole-derived chalcones containing aromatic amide substituent were designed and synthesized. All of the chalcone compounds were tested for their in vitro antitumor activity against human cancer cell lines (HCT116, HepG2, A549, and CRL-5908). The antiproliferative activity of compounds 3, 6, 9, 14, 15, 16 against HCT116 cells was significantly better than that that of 5-Fluorouracil (IC50: 94.63 μM). The antitumor activity of these compounds showed obvious differences between the wild type HCT116 and mutant HCT116 (TP53-/-) cells. A preliminary mechanistic study suggested that these compounds act by upregulating the expression of TP53 protein in tumor cells without inhibiting the MDM2-TP53 interaction.

A Swift One-Pot Solvent-Free Synthesis of Benzimidazole Derivatives and Their Metal Complexes: Hydrothermal Treatment, Enzymatic Inhibition, and Solubilization Studies

Abstract: Three benzimidazole derivatives, 1-(1H-benzimidazol-2-yl)ethanol (HBE), 1H-benzimidazol-2-yl(diphenyl)methanol (BDM) and 1,2-bis(1H-benzimidazol-2-yl)ethane-1,2-diol (BHBED), have been synthesized following the one-pot rapid green protocol. Complexes of benzimidazole derivatives with six 3d transition metals, Cu(II), Mn(II), Zn(II), Fe(II), Co(II), and Ni(II), have been synthesized by free hydrothermal method. The synthesized products have been characterized by FTIR, 1H, and 13C NMR, and mass spectroscopy, and CHN analysis, and 2:1 ligand to metal stoichiometry has been confirmed. The synthesized ligands and metal complexes have been tested for antioxidant potential (DPPH), inhibitory activity including inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), lipoxygenase (LOX), α-glucosidase. Micellar solubilization of the metal complexes has been studied in sodium dodecyl sulphate (SDS) by UV-Vis spectroscopy and conductivity. The selected complexes of nickel, zinc and cobalt have demonstrated interaction with SDS, and the value of critical micellar concentration increased in all cases.

Synthesis and antibacterial activity of some novel 6-(1H-benz[d] imidazol-2-yl)-8-(5-nitro-2-furyl)-3-(4-pyridyl)-7,8-dihydro[1,2,4] triazolo[3,4-b][1,3,4]thiadiazepines

A new series of novel 6-(1H-benz[d]imidazol-2-yl)-8-(5-nitro-2-furyl)-3-(4- pyridyl)-7,8-dihydro[1,2,4]triazolo[ 3,4-b][1,3,4]thiadiazepines 8a - d has been synthesized. These compounds were evaluated for their efficiency as antibacterial agents against two Gram-positive and Gram-negative strains of bacteria along with anti-fungal activity against two fungal organisms. The antibacterial and antifungal activities of the present compounds were not comparable with those of the standard drugs employed. But, however, all the test compounds could exhibit notable activities only at higher concentrations (250, 500 μg/ml). The chemical structures of these compounds were confirmed on the basis of spectral data.

Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and deadliest cancers in the world. Currently, sorafenib is the only drug that has been approved by the U.S. FDA for patients with advanced HCC. However, its improvement on patient outcomes is modest, and the median survival time is only prolonged 2-3 months. In addition, the application of sorafenib is limited because of its high cost and severe adverse side-effects. Therefore, developing more effective novel agents and reducing the dosage of sorafenib are urgently needed for HCC therapy. Here, a novel benzimidazole derivative (4a) bearing a pyrolidine side chain (9a) was synthesized. The treatments of compounds 4a, 9a and sorafenib either alone or in combination on the inhibition of liver cancer cells proliferation were measured using alamarBlue cell viability and trypan blue staining assay. Intracellular signaling pathway activities were assessed by Western blot, Q-PCR and IHC staining. The HuH7 xenograft model was used to examine antitumor activity in vivo. Adverse effects (e.g., changes in body weight, serum parameters, liver function and pathology) of mice treated with 9a were also evaluated. Compound 9a significantly inhibited HCC cell proliferation compared with 4a. In addition, 9a strongly synergized with a low dose of sorafenib in suppressing HCC cell proliferation. Regarding the activities of the signaling pathways, sorafenib did not suppress AKT signaling; however, 9a inhibited AKT and its downstream phosphorylation of p70S6K. In addition, treatment with either 9a alone or in combination with sorafenib led to the inhibition of JNK phosphorylation. However, there were no effects on the inhibition of apoptosis. The in vivo HuH7 xenograft model showed that the administration of 9a plus a low dose of sorafenib significantly decreased expression of the HCC markers α-fetoprotein, glypican-3 and survivin as well as suppressed tumor growth. Finally, there were no adverse effects in mice treated with 9a. In conclusion, co-treatment with a novel benzimidazole derivative bearing a pyrolidine side chain in combination with a low dose of sorafenib exerted significant antitumor activity in preclinical HCC models, which potentially suggests its use as a novel therapeutic strategy for patients with HCC.

A step-by-step synthesis of triazole-benzimidazole-chalcone hybrids: Anticancer activity in human cells+

Novel series of triazole-benzimidazole-chalcone hybrid compounds have been synthesized via click chemistry, between different azide derivatives and substituted benzimidazole terminal alkynes bearing a chalcone moiety. The starting alkynes are prepared via base-catalysed nitrogen alkylation of pre-synthetized benzimidazole-chalcone substrates. All the intermediates as well as the final products are fully characterized by 1D and 2D NMR and mass spectrometry techniques. HMBC correlations permits the identification of a unique 1,4-disubstitued triazole-benzimidazole-chalcone isomer. Evaluation of the anti-proliferative potential in breast and prostate cancer cell lines showed that the presence of chloro substituents at the chalcone ring of the triazole-benzimidazole-chalcone skeleton enhanced the cytotoxic effects. The benzyl group linked to the 1,2,3-triazole moiety provides more antiproliferative potential.

Design and synthesis of novel 2-(5-(4-aryl)-4,5-dihydro-1H-pyrazol-3-yl)-1-(substituted aminomethyl)-1H-benzimidazole as potent anticonvulsants

A variety of novel 2-(5-(4-aryl)-4,5-dihydro-1H-pyrazol-3-yl)-1-(substitutedaminomethyl)-1H-benzimidazole 5a–5l have been synthesized from o-phenylenediamine by a multi-step synthesis. Antiepileptic screening of the title compounds was performed using maximal electroshock and subcutaneous pentylenetetrazole seizures tests while the neurotoxicity was determined by rotorod test. In the preliminary screening, compounds 5d, 5e, 5f and 5l were found active in maximal electroshock model; while 5d, 5e, 5f and 5k showed significant antiepileptic activity in subcutaneous pentylenetetrazole seizure model. Further all these five compounds were administered to rats at 30 mg/kg dose in oral route and found that compounds 5e and 5f showed better activity than Phenytoin. These compounds 5e and 5f revealed protection in maximal electroshock after intraperitoneal administration at a dose of 30 mg/kg (0.5 h and 4.0 h). These compounds also provided protection in the subcutaneous pentylenetetrazole seizure at a dose of 100 mg/kg (0.5 h) and 300 mg/kg (4 h).

Dinuclear Hg(II) complex of new benzimidazole-based Schiff base: one-pot synthesis, crystal structure, spectroscopy, and theoretical investigations

A new dinuclear complex, [HgCl2L]2, was prepared using a Schiff base derived from benzimidazole (L = [1-(1H-benzo[d]imidazol-2-yl)-N-(4-methoxyphenyl)ethan-1-imine]. The mercury complex was obtained in good yield by one-pot reaction

Design and structure-activity relationships anticandidosic of diazaheteroaryl functionalized by Micha?l acceptors

Benzimidazole and imidazopyridine heterocycles associated with Micha?l acceptors have shown strong anticandidosic potential in our previous work. After a decade of research, we have designed, synthesized and evaluated the anticandidosic activities of seve

Probe and method for fluorescent visual recognition of latent fingerprints on substrate

The invention belongs to the technical field of fingerprint recognition, and particularly relates to a probe and method for fluorescent visual recognition of latent fingerprints on a substrate. The fluorescent probe is a clamp-type Zn (II) metal organic complex, 2, 2': 6', 2''-terpyridyl or 2, 6-diimidazolyl pyridine is used as a framework, and different substituent groups are introduced to the 4' position. The fluorescent probe can be used for carrying out fluorescent visual recognition on latent fingerprints on different substrate surfaces, specifically, the substrate with the fingerprints is soaked in a probe solution or a probe aqueous solution is uniformly sprayed on the surface of the substrate, clear and bright fingerprint lines and detail characteristics can be observed under excitation of 365nm ultraviolet light, and the fluorescent probe is suitable for fingerprint color development identification. The fluorescent probe can emit fluorescence of different colors in a pure water phase by changing substituent groups, the fluorescence emission wavelength is adjusted to be located in different visible light regions, and self-fluorescence interference of a color developing substrate is overcome; and the probe is simple and convenient to synthesize, low in cost, low in toxicity and environment-friendly.

Preparation method of thiabendazole intermediate

The invention provides a preparation method of a thiabendazole intermediate. The method uses a raw material containing o-phenylenediamine to prepare the thiabendazole intermediate shown as a formula (1), and comprises the following steps: in an acidic environment, carrying out condensation reaction on the raw material containing o-phenylenediamine to obtain a crude product 1; carrying out halogenation reaction on the crude product 1 to obtain a crude product 2; and carrying out decarboxylation reaction on the crude product 2, and purifying to obtain the thiabendazole intermediate. According tothe invention, the method is low in raw material cost, simple in synthetic route, inapplicable to catalysts, recyclable in solvent, almost zero in emission of three wastes, mild in reaction condition, simple to operate and suitable for modern industrial production, and the influence on the environment is avoided, and the yield is as high as 80% or above. R is Cl or Br.